First central oncology lab for clinical trials opens in Malaysia

Hematogenix, the first central oncology laboratory for clinical trials in Malaysia, has been formally launched. This is expected to move local pharmaceutical and healthcare industries further up the value chain into research and development (R&D) and related services. Hematogenix, a Global Clinical Research Central Laboratory specialising in Oncology/Cancer Research with accreditations from College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA), has been in operation globally since 2007 and in Malaysia since June 2021. Hematogenix is headquartered in Chicago, Illinois with three other branches globally, covering the European market in Manchester, United Kingdom, the China market in Shanghai; and the latest market for Asia Pacific is in Cyberjaya, Malaysia.